All secondary end points showed TCZ-SC to be superior to PBO-SC , including ACR50 and ACR70 response ( 40 % and 20 % for TCZ-SC , respectively , and 12 % and 5 % for PBO-SC , respectively ; P < 0.0001 for both ) and Disease Activity Score in 28 joints ( DAS28 ) remission ( DAS28 < 2.6 ; 32 % versus 4 % [ P < 0.0001 ] ) .